医药生物行业动态报告:医药行业周度复盘

中信建投证券
Aug 26

核心观点:本周制药行业表现一般,恒瑞医药发布2025年半年度报告,业绩增长良好;信达生物小分子GLP-1R激动剂在中国获批临床;荣昌生物宣布将其VEGF/FGF双靶点融合蛋白RC28-E在多个亚太地区的权益以14亿元总额授权给参天制药;普米斯/BioNTech公布BNT327首个全球针对SCLC的II期数据。医疗器械板块本周部分个股涨跌主要与中报业绩披露有关,脑机接口概念股有所回调;接下来看好...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10